Levodopa/Carbidopa/Entacapone Biogaran

Levodopa, Carbidopa, Entacapone, the active ingredients in Levodopa/Carbidopa/Entacapone Biogaran, are an antiparkinson agent presented as an oral tablet for oral use. The combination is prescribed to manage Parkinson's disease symptoms by enhancing central dopamine levels. It is indicated for patients with fluctuating motor response who require more stable dopaminergic stimulation.

GNH USA supplies Levodopa/Carbidopa/Entacapone Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured medication to hospitals, pharmacies and clinics worldwide, with adherence to EU GMP standards and robust logistics for timely delivery.

Levodopa/Carbidopa/Entacapone is an antiparkinson combination used to manage motor symptoms in Parkinson's disease. - Parkinson's disease (motor fluctuations): reduces OFF time and increases ON time with more stable symptom control. - Parkinson's disease (early adjunct therapy): enhances levodopa efficacy when added to existing regimen. - Parkinson's disease (advanced disease): provides sustained dopaminergic stimulation to improve daily motor function.

Adverse reactions may occur with any antiparkinson therapy and should be monitored.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Headache - Orthostatic hypotension - Insomnia

Serious or Rare Side Effects: - Severe hypotension or syncope - Cardiac arrhythmias - Neuroleptic malignant‑like syndrome - Severe psychiatric disturbances (hallucinations, psychosis) - Dyskinesia - Allergic reactions including rash or angioedema

Use of Levodopa/Carbidopa/Entacapone requires careful clinical monitoring. - Monitor blood pressure: watch for orthostatic hypotension, especially at treatment initiation. - Assess psychiatric status: risk of hallucinations, confusion, or worsening psychosis. - Evaluate liver function: entacapone may affect hepatic enzymes; periodic testing is advised. - Adjust dose in renal impairment: consider reduced clearance and potential accumulation. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Levodopa/Carbidopa/Entacapone can interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may exacerbate confusion and cognitive decline. - CNS depressants: increase sedation and dizziness. - High‑protein meals: reduce levodopa absorption and efficacy. - Iron or mineral supplements: chelate levodopa and diminish its bioavailability.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): possible serotonin syndrome. - Antihypertensives: additive blood‑pressure lowering effects. - Antipsychotics (dopamine antagonists): may diminish therapeutic response. - CYP2C9 inhibitors (e.g., fluconazole): raise entacapone plasma levels. - Diuretics: may alter electrolyte balance and affect blood‑pressure control.